key: cord-0854792-f9v61j9f
authors: Nishizawa, Yoshiki; Hoshina, Yoji; Baker, Virginia
title: Bell’s palsy following the Ad26.COV2.S COVID-19 vaccination
date: 2021-05-20
journal: QJM
DOI: 10.1093/qjmed/hcab143
sha: 869ecbb95af1548567c6ed31e50bc5b5fd5449a8
doc_id: 854792
cord_uid: f9v61j9f

nan

Learning point:

We describe a case of Bell's palsy after Janssen COVID19 (Ad26.CoV2.S) vaccination. To the best of our knowledge, this is the first case report describing an incidence of Bell's palsy after the injection of Ad26.CoV2.S vaccination, and we highlight this case to further discussion and review.

A 62-year-old Pilipino female with a past medical history of type 2 diabetes mellitus, hypertension, and hyperlipidemia presented to the emergency department with a 2 day history of right facial droop 20 days following the Ad26.COV2.S vaccination. The patient denied prior history of stroke, transient ischemic attack, Bell's palsy, or other unexplained neurological symptoms. She also denied any recent viral infection or facial trauma. At the time of presentation, she denied tingling, ear pain, hearing loss, dysgeusia, drooling, vision problems, or rashes. Her physical examination was notable for near-complete paralysis of the right lower face and significant paralysis of the right upper face with incomplete eye closure, consistent with a House-Brackmann score 4 Bell's Palsy ( Figure 1 ). Her motor, sensory, gait, and cerebellar examination were otherwise normal. Head computed tomography (CT) and brain magnetic resonance imaging (MRI) were unremarkable, without infarct, demyelination or peripheral nerve enhancement. She was diagnosed with Bell's Palsy related to COVID-19 vaccination.

Although most cases are idiopathic, peripheral facial nerve palsy can be observed in the context of viral infection, trauma, pregnancy and other inflammatory, autoimmune and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 neoplastic conditions. Facial nerve palsy has also been reported as an adverse event following vaccination, most often following the influenza vaccine. 1,2, We report a patient who developed facial nerve palsy 20 days after the administration of the Janssen coronavirus (Ad26.COV2.S) vaccine. Although we cannot directly attribute our patient's presentation to the vaccine, her presentation was temporally related. We believe that this case can bring awareness to a potential adverse effect, and we highlight this case to further discussion and review. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 We present the first case report describing an incidence of Bell's Palsy after the Janssen Ad26.COV2.S vaccination. This case highlights the importance of continuing to monitor for side effects and complications on an individual basis following this novel vaccine.

Written informed consent was obtained from the patient for publication of this case report and accompanying images.

The authors received no financial support for the research, authorship, and/or publication of this article.

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article

Written informed consent was obtained from the patient for publication of this report and accompanying images. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 

Brighton Collaboration Bell's Palsy Working Group. Facial nerve palsy including Bell's palsy: Case definitions and guidelines for collection, analysis, and presentation of immunisation safety data

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

Fact sheet for healthcare providers administering vaccine (vaccination providers) Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease (COVID-19)

ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Manuscripts submitted to QJM

The authors thank the patient for allowing us to publish this case report. 

None declared.